Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Goepfert

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Plos Pathogens|January 9, 2015
Transmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV-1 recipientsLing Yue, Katja J Pfafferott, Joshua Baalwa, et al.
Vaccine|July 7, 2021
AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest periodYunda Huang, Kelly E Seaton, Martin Casapia, et al.
Annals of Internal Medicine|April 28, 2025
High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302)Sharon A Riddler, Zoe Moodie, Jesse Clark, et al.
Plos One|August 23, 2011
A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)Gavin J Churchyard, Cecilia Morgan, Elizabeth Adams, et al.
Science (New York, N.Y.)|July 12, 2014
HIV transmission. Selection bias at the heterosexual HIV-1 transmission bottleneckJonathan M Carlson, Malinda Schaefer, Daniela C Monaco, et al.
JAMA Network Open|January 23, 2023
Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine TrialsAlfredo J Mena Lora, Jessica E Long, Yunda Huang, et al.
Vaccine|January 5, 2025
Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimensHana M El Sahly, Evan J Anderson, Lisa A Jackson, et al.
JAMA Network Open|July 13, 2023
Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical TrialsDeborah A Theodore, Angela R Branche, Lily Zhang, et al.
Emerging Infectious Diseases|July 1, 2021
Predictors of Nonseroconversion after SARS-CoV-2 InfectionWeimin Liu, Ronnie M Russell, Frederic Bibollet-Ruche, et al.
Plos Medicine|March 19, 2024
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trialZoe Moodie, Erica Andersen-Nissen, Nicole Grunenberg, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Plos Pathogens|January 9, 2015
Transmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV-1 recipientsLing Yue, Katja J Pfafferott, Joshua Baalwa, et al.
Vaccine|July 7, 2021
AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest periodYunda Huang, Kelly E Seaton, Martin Casapia, et al.
Annals of Internal Medicine|April 28, 2025
High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302)Sharon A Riddler, Zoe Moodie, Jesse Clark, et al.
Plos One|August 23, 2011
A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)Gavin J Churchyard, Cecilia Morgan, Elizabeth Adams, et al.
Science (New York, N.Y.)|July 12, 2014
HIV transmission. Selection bias at the heterosexual HIV-1 transmission bottleneckJonathan M Carlson, Malinda Schaefer, Daniela C Monaco, et al.
JAMA Network Open|January 23, 2023
Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine TrialsAlfredo J Mena Lora, Jessica E Long, Yunda Huang, et al.
Vaccine|January 5, 2025
Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimensHana M El Sahly, Evan J Anderson, Lisa A Jackson, et al.
JAMA Network Open|July 13, 2023
Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical TrialsDeborah A Theodore, Angela R Branche, Lily Zhang, et al.
Emerging Infectious Diseases|July 1, 2021
Predictors of Nonseroconversion after SARS-CoV-2 InfectionWeimin Liu, Ronnie M Russell, Frederic Bibollet-Ruche, et al.
Plos Medicine|March 19, 2024
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trialZoe Moodie, Erica Andersen-Nissen, Nicole Grunenberg, et al.
Pageof 6